In this insightful article in The Lancet, editor Jacqueline Duda spoke with our CEO, Richard Jones, and Head of BD, Dr. Martina Kalle-Brune, about the pressing need for innovative strategies to combat sepsis. Read the
J.P. Morgan Week & Biotech Showcase 13 – 16 January | San Francisco, California, USA Meet the AdrenoMed team in San Francisco. Link to J.P.Morgan Healthcare Conference Link to Biotech Showcase
AdrenoMed will attend the 2024 World Sepsis Day Symposium on Wednesday, September 11, 2024. On the margins of the 2024 World Sepsis Day, the Global Sepsis Alliance and the European Sepsis Alliance are joining the Sepsis
3CT 2024 – Critical Care Clinical Trialists Workshop13-15 June| Wahsington DC, USA Vist the 3CT website.
Hennigsdorf/Berlin (Germany), April 10, 2024 –AdrenoMed AG, the vascular integrity company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing
The article was published by David Wild, In Vivo, Citeline Commercial.
ISICEM 2024 – International Symposium on Intensive Care & Emergency Medicine18-21 March | Brussels, Belgium Meet the AdrenoMed team in Brussels Link to ISICEM
By loading the map, you agree to Google's privacy policy.
Learn more
© 2024 AdrenoMed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung | Expanded Access Policy
